Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Meribank Biotech CoROCO:4724 -3.65%40 Gross Margin % is 38.81% as of Dec. 2025, which is 31% below its 10-year median of 56.51. GuruFocus rates ROCO:4724 with a GF Score™ of 40/100 and a GF Value™ of NT$48.90 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 732 Biotechnology companies, Meribank Biotech Co ranks worse than 66.8% on this metric.
Meribank Biotech Co Ltd gross margin has been in long-term decline. The average rate of decline per year is -4.5%.
The historical rank and industry rank for Meribank Biotech Co's Gross Margin % or its related term are showing as below:
ROCO:4724'
s Gross Margin % Range Over the Past 10 Years
Min: 42.86 Med: 56.51 Max: 63.02
Current: 42.86
During the past 8 years, the highestGross Margin % of Meribank Biotech Co was 63.02%. The lowest was 42.86%. And the median was 56.51%.
ROCO:4724's Gross Margin % is ranked worse than 66.8% of 732
companies
in the Biotechnology industry
Industry Median: 60.905
vs ROCO:4724: 42.86
Meribank Biotech Co had a gross margin of 38.81% for the quarter that ended in Dec. 2025 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for Meribank Biotech Co was -4.50% per year.
Meribank Biotech Co (ROCO:4724) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Meribank Biotech Co had a gross margin of 38.81% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Meribank Biotech Co Gross Margin % Related Terms
Meribank Biotech Co Gross Margin % Historical Data
* Premium members only.
The historical data trend for Meribank Biotech Co's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4724 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Meribank Biotech Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Meribank Biotech Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Meribank Biotech Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Meribank Biotech Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Meribank Biotech Co (ROCO:4724) has a Gross Margin % of 38.81% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Meribank Biotech Co and its competitors. This is 31% below median its historical median of 56.51. Over the past decade, Meribank Biotech Co's Gross Margin % has ranged from 42.86 to 63.02. According to the industry distribution chart, Meribank Biotech Co ranks #489 out of 732 companies in the Biotechnology industry, placing it in the top 66.8%.
Is Meribank Biotech Co's Gross Margin % too high?
Meribank Biotech Co's current Gross Margin % of 38.81% is 31% below median its 10-year median of 56.51. Over the past 10 years, this metric has ranged from a low of 42.86 to a high of 63.02. The Biotechnology industry median Gross Margin % is 60.91. Meribank Biotech Co's value of 38.81% is 36.3% below this industry median. Based on the distribution chart, Meribank Biotech Co ranks #489 out of 732 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Meribank Biotech Co has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Meribank Biotech Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Meribank Biotech Co ranks #489 out of 732 companies for Gross Margin %. This places Meribank Biotech Co in the lower half of its industry. The industry median Gross Margin % is 60.91. Meribank Biotech Co's value of 38.81% is 36.3% below this benchmark. Historically, Meribank Biotech Co's own Gross Margin % has ranged from 42.86 to 63.02 over the past decade. While the company's 10-year median is 56.51 vs. the industry median of 60.91, Meribank Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Meribank Biotech Co's current Gross Margin % of 38.81% is 36.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Meribank Biotech Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Meribank Biotech Co's current Gross Margin % is 38.81%, which is 31% below median its own 10-year median of 56.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Meribank Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Meribank Biotech Co (ROCO:4724) is currently considered Possible Value Trap. The stock's GF Value™ is NT$48.90, compared to a current price of NT$9.78 — trading 80% below its estimated fair value. The current Gross Margin % is 38.81%, which is 31% below median its 10-year median of 56.51 and 36.3% below the Biotechnology industry median of 60.91. Meribank Biotech Co's overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Meribank Biotech Co (ROCO:4724), the current Gross Margin % is 38.81% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Meribank Biotech Co (ROCO:4724) Overvalued in 2026?
Based on GuruFocus' analysis, Meribank Biotech Co stock appears to be undervalued.
The current stock price of NT$9.78 is trading 80% below its estimated GF Value™ of NT$48.90.
GuruFocus considers Meribank Biotech Co to be Possible Value Trap.
Key valuation signals for ROCO:4724:
Gross Margin %: 38.81% (31% below median its 10-year median of 56.51)
GF Value™: NT$48.90 vs. price of NT$9.78 (80% below fair value)
Industry Position: 36.3% below the Biotechnology median (#489 of 732)
No single metric tells the full story. See the ROCO:4724 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Meribank Biotech Co Ltd is engaged in Research and development and sales of new cell drugs and also Umbilical cord blood, placenta and umbilical cord mesenchymal stem cells processing, testing and cryopreservation.
40GF Score
Get the complete analysis for ROCO:4724
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4724 has been successfully added to your 
